Coya Therapeutics shares jump 10.83% premarket as COYA 303 shows potent anti-inflammatory efficacy in animal study.

Coya Therapeutics (NASDAQ: COYA) surged 10.83% in premarket trading following the announcement that its experimental drug candidate, COYA 303, demonstrated potent systemic and brain anti-inflammatory efficacy in a preclinical animal study. The combination therapy, which pairs low-dose IL-2 with a GLP-1 receptor agonist, reduced peripheral inflammation, enhanced regulatory T cell function, and shifted macrophages to an anti-inflammatory phenotype. The results validate the company’s dual immunomodulatory approach and highlight potential applications in neurodegenerative diseases like Alzheimer’s. The data strengthens Coya’s pipeline and aligns with growing interest in GLP-1-based therapies, positioning COYA 303 as a next-generation treatment candidate. The positive preclinical findings directly correlate with the stock’s sharp premarket rise, reflecting investor optimism about the therapy’s development prospects.